{"data":{"id":"us/21-cfr-336.80","jurisdiction":"us","citation":"21 CFR 336.80","heading":"Professional labeling.","body":"The labeling provided to health professionals (but not to the general public) may contain the following additional indications.\n(a) For products containing cyclizine hydrochloride, dimenhydrinate, and diphenhydramine hydrochloride identified in § 336.10 (a), (b), and (c). “For the treatment of vertigo of motion sickness.”\n(b) For products containing meclizine hydrochloride identified in § 336.10(d). “For the treatment of vertigo.”","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER D—DRUGS FOR HUMAN USE","PART 336—ANTIEMETIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE","Subpart C—Labeling"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"afe4f940f53a3874278bb13ecdd1456e54045d009577b076c7d752218d3359bf","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-336.50","next":"us/21-cfr-338.1"},"notice":"GroundRules: Original legal text. Not legal advice."}